Research graph
References from Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3390/v11030210
10.3390/v11030210 · External reference
10.1016/s0140-6736(20)30251-8
10.1016/s0140-6736(20)30251-8 · External reference
10.1016/s0140-6736(20)30185-9
10.1016/s0140-6736(20)30185-9 · External reference
SARS pandemic and the 2020 novel coronavirus epidemic in China
2003 · External reference
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet
2020 · External reference
A genomic perspective on the origin and emergence of SARS-CoV-2
2020 · External reference
Asymptomatic cases in a family cluster with SARS-CoV-2 infection
10.1016/s1473-3099(20)30114-6 · 2020 · External reference
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges
2020 · External reference
A review of coronavirus disease-2019 (COVID-19)
2020 · External reference
Coronavirus disease: A review of a new threat to public health
2020 · External reference
Emerging coronaviruses: genome structure, replication, and pathogenesis
10.1002/jmv.26234 · 2020 · External reference
A new virus isolated from the human respiratory tract
10.3181/00379727-121-30734 · 1966 · External reference
Growth in suckling-mouse brain of“ IBV-like” viruses from patients with upper respiratory tract disease
10.1073/pnas.58.6.2268 · 1967 · External reference
Bat origin of human coronaviruses
2015 · External reference
10.1038/cr.2013.92
10.1038/cr.2013.92 · External reference
A rapid and specific assay for the detection of MERS-CoV
10.3389/fmicb.2018.01101 · 2018 · External reference
Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China
10.1186/s13054-020-02895-6 · 2020 · External reference
Emerging Manufacturers engagements in the COVID-19 vaccine research, development and supply
10.1016/j.vaccine.2020.06.022 · 2020 · External reference
10.1038/s41591-020-0820-9
10.1038/s41591-020-0820-9 · External reference
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV
2020 · External reference
Coronavirus disease (COVID-19) and prevalence of chronic liver disease: A meta-analysis
2019 · External reference
Epidemiological characteristics of COVID-19: a systematic review and meta-analysis
10.1017/s0950268820001430 · 2020 · External reference
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
10.1016/s2213-8587(20)30238-2 · 2020 · External reference
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet
2020 · External reference
The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020
10.46234/ccdcw2020.032 · 2020 · External reference
Coronavirus disease 2019 and gender-related mortality in European countries: A meta-analysis
10.1016/j.maturitas.2020.06.017 · 2020 · External reference
Singapore COVID-19 pandemic response as a successful model framework for low-resource health care settings in Africa? OMICS: A Journal of
2020 · External reference
Unresolved reference
External reference
Estimation of exponential growth rate and basic reproduction number of the coronavirus disease 2019 (COVID-19) in Africa
10.1186/s40249-020-00718-y · 2020 · External reference
10.1038/s41564-020-0695-z
10.1038/s41564-020-0695-z · External reference
Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses
2020 · External reference
History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic
2020 · External reference
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7 · External reference
Possible bat origin of severe acute respiratory syndrome coronavirus 2
10.3201/eid2607.200092 · 2020 · External reference
10.1016/j.meegid.2020.104212
10.1016/j.meegid.2020.104212 · External reference
Molecular evolution and phylogenetic analysis of SARS-CoV-2 and hosts ACE2 protein suggest Malayan pangolin as intermediary host
2020 · External reference
Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence
2020 · External reference
10.1016/j.meegid.2020.104351
10.1016/j.meegid.2020.104351 · External reference
10.1136/bmj.m4857
10.1136/bmj.m4857 · External reference
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
10.1016/j.cell.2020.08.012 · 2020 · External reference
Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus
10.1016/j.cell.2020.06.043 · 2020 · External reference
10.1080/22221751.2020.1719902
10.1080/22221751.2020.1719902 · External reference
10.3389/fmicb.2020.00298
10.3389/fmicb.2020.00298 · External reference
10.1038/nsmb1123
10.1038/nsmb1123 · External reference
10.1128/jvi.01467-06
10.1128/jvi.01467-06 · External reference
10.1128/jvi.01331-15
10.1128/jvi.01331-15 · External reference
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein
10.1128/jvi.68.9.5403-5410.1994 · 1994 · External reference
10.1128/jvi.00127-20
10.1128/jvi.00127-20 · External reference
10.1128/jvi.05300-11
10.1128/jvi.05300-11 · External reference
10.1073/pnas.0809524106
10.1073/pnas.0809524106 · External reference
10.1128/jvi.77.16.8801-8811.2003
10.1128/jvi.77.16.8801-8811.2003 · External reference
10.1128/jvi.02501-05
10.1128/jvi.02501-05 · External reference
10.1128/jvi.79.9.5288-5295.2005
10.1128/jvi.79.9.5288-5295.2005 · External reference
10.1128/jvi.01358-06
10.1128/jvi.01358-06 · External reference
10.1016/s0022-2836(03)00865-9
10.1016/s0022-2836(03)00865-9 · External reference
10.1083/jcb.124.1.55
10.1083/jcb.124.1.55 · External reference
Unresolved reference
2020 · External reference
10.2217/fon-2020-0571
10.2217/fon-2020-0571 · External reference
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
10.1016/j.cell.2020.02.052 · 2020 · External reference
Features, evaluation and treatment coronavirus (COVID-19). StatPearls [Internet]
2020 · External reference
10.1007/s00281-017-0629-x
10.1007/s00281-017-0629-x · External reference
COVID-19: consider cytokine storm syndromes and immunosuppression
2020 · External reference
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
2020 · External reference
Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia
2020 · External reference
10.1002/jmv.25689
10.1002/jmv.25689 · External reference
Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review
10.1001/jama.2020.12839 · 2020 · External reference
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
2020 · External reference
10.1016/s0140-6736(20)30183-5
10.1016/s0140-6736(20)30183-5 · External reference
Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis
2020 · External reference
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
2020 · External reference
10.1016/s0140-6736(20)30211-7
10.1016/s0140-6736(20)30211-7 · External reference
10.1148/radiol.2020200236
10.1148/radiol.2020200236 · External reference
Emerging 2019 novel coronavirus (2019-nCoV) pneumonia
10.1148/radiol.2020200274 · 2020 · External reference
Lipid rafts are involved in SARS-CoV entry into Vero E6 cells
10.1016/j.bbrc.2008.02.023 · 2008 · External reference
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses
10.1172/jci1368 · 1998 · External reference
Tocilizumab treatment in COVID-19: A single center experience
10.1002/jmv.25801 · 2020 · External reference
Emergence of a novel coronavirus disease (COVID-19) and the importance of diagnostic testing: why partnership between clinical laboratories, public health agencies, and industry is essential to control the outbreak
10.1093/clinchem/hvaa071 · 2020 · External reference
Discovery of bat coronaviruses through surveillance and probe capture-based next-generation sequencing
2020 · External reference
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
10.1016/s2665-9913(20)30173-9 · 2020 · External reference
Evaluation of RdRp & ORF-1b-nsp14-based real-time RT-PCR assays for confirmation of SARS-CoV-2 infection: An observational study
10.4103/ijmr.ijmr_1256_20 · 2020 · External reference
A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2
10.1016/j.heliyon.2020.e04405 · 2020 · External reference
10.1177/2472555220942123
10.1177/2472555220942123 · External reference
Limits of detection of 6 approved RT–PCR kits for the novel SARS-Coronavirus-2 (SARS-CoV-2)
10.1093/clinchem/hvaa099 · 2020 · External reference
Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19)
2020 · External reference
10.1136/bmj.m3340
10.1136/bmj.m3340 · External reference
Risk of reactivation or reinfection of novel coronavirus (COVID-19)
2020 · External reference
Mini Review: Recent progress in RT-LAMP enabled COVID-19 detection
2020 · External reference
Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19
10.3389/fcimb.2020.00331 · 2020 · External reference
Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19
2020 · External reference
Standard operating procedures for SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay
2020 · External reference
A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples
2020 · External reference
Molecular immune pathogenesis and diagnosis of COVID-19
2020 · External reference
Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: A narrative review
2020 · External reference
Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2
2020 · External reference
Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In Covid-19 Patients Semiquantitatively
2020 · External reference
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
10.2807/1560-7917.es.2020.25.16.2000421 · 2020 · External reference
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
2020 · External reference
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department
10.1002/jmv.25800 · 2020 · External reference
Unresolved reference
2020 · External reference
Evolution of the COVID-19 vaccine development landscape
2020 · External reference
Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
2020 · External reference
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
2020 · External reference
10.1001/jama.2020.10245
10.1001/jama.2020.10245 · External reference
10.1016/s1473-3099(20)30141-9
10.1016/s1473-3099(20)30141-9 · External reference
10.1172/jci138745
10.1172/jci138745 · External reference
Peptide-like and small-molecule inhibitors against Covid-19
2020 · External reference
Oligonucleotides and the COVID-19 Pandemic: A Perspective
2020 · External reference
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons
2020 · External reference
Type I and Type III Interferons-Induction, Signaling, Evasion, and Application to Combat COVID-19
10.1016/j.chom.2020.05.008 · 2020 · External reference
New insights into the antiviral effects of chloroquine
10.1016/s1473-3099(06)70361-9 · 2006 · External reference
10.1038/cr.2012.165
10.1038/cr.2012.165 · External reference
Effects of chloroquine on viral infections: an old drug against today's diseases
10.1016/s1473-3099(03)00806-5 · 2003 · External reference
10.1007/s00535-009-0132-9
10.1007/s00535-009-0132-9 · External reference
Chloroquine interferes with dengue-2 virus replication in U937 cells
10.1111/1348-0421.12154 · 2014 · External reference
10.3390/v8120322
10.3390/v8120322 · External reference
10.1099/jgv.0.000309
10.1099/jgv.0.000309 · External reference
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
10.1186/1743-422x-2-69 · 2005 · External reference
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis
2020 · External reference
Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
10.1016/j.therap.2020.05.010 · 2020 · External reference
10.1101/2020.04.10.20060558
10.1101/2020.04.10.20060558 · External reference
Unresolved reference
External reference
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Review of Anti-infective
2020 · External reference
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
10.1016/j.jiph.2020.07.013 · 2020 · External reference
Favipiravir, an antiviral for COVID-19?
10.1093/jac/dkaa171 · 2020 · External reference
10.1021/acscentsci.0c00272
10.1021/acscentsci.0c00272 · External reference
Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized
2020 · External reference
10.1056/nejmoa2001282
10.1056/nejmoa2001282 · External reference
Remdesivir for the treatment of Covid-19—preliminary report
2020 · External reference
Experimental treatment with favipiravir for COVID-19: an open-label control study
2020 · External reference
Unresolved reference
2010 · External reference
Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review
10.1002/ptr.6178 · 2018 · External reference
Nutraceutical value of salad vegetables to combat COVID 19
2020 · External reference
Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2
10.1038/s41598-020-74715-4 · 2020 · External reference
Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development
2020 · External reference
Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19
2020 · External reference
Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication
2020 · External reference
A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2
2020 · External reference
10.20944/preprints202003.0349.v1
10.20944/preprints202003.0349.v1 · External reference
Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis
10.1046/j.1440-1746.2002.02876.x · 2002 · External reference
Unresolved reference
2021 · External reference
10.1159/000069334
10.1159/000069334 · External reference
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective
10.7150/ijbs.45538 · 2020 · External reference
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction
2020 · External reference
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
2020 · External reference
10.1136/annrheumdis-2020-218122
10.1136/annrheumdis-2020-218122 · External reference
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
10.1128/aac.00754-20 · 2020 · External reference
Interferon beta-1b for COVID-19
10.1016/s0140-6736(20)31101-6 · 2020 · External reference
10.1001/jama.2020.10699
10.1001/jama.2020.10699 · External reference
10.1073/pnas.2006961117
10.1073/pnas.2006961117 · External reference
The Uncertain Role of Corticosteroids in the Treatment of COVID-19. JAMA
2020 · External reference
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
2020 · External reference
Coronavirus vaccines: five key questions as trials begin
10.1038/d41586-020-00798-8 · 2020 · External reference
10.1126/science.abb2507
10.1126/science.abb2507 · External reference
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
2020 · External reference
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
2020 · External reference
Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study
2020 · External reference
BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies
10.1016/j.jaci.2014.02.028 · 2014 · External reference
10.1136/bmj.m1679
10.1136/bmj.m1679 · External reference
Researchers strive to recruit hard-hit minorities into COVID-19 vaccine trials
2020 · External reference
Progress and concept for COVID-19 vaccine development
2020 · External reference
Unresolved reference
2020 · External reference
The SARS-CoV-2 vaccine pipeline: an overview
2020 · External reference
10.1136/bmj.m3226
10.1136/bmj.m3226 · External reference
The Russian vaccine for COVID-19. The Lancet
2020 · External reference
10.1016/j.nantod.2020.101019
10.1016/j.nantod.2020.101019 · External reference
10.2217/nnm-2020-0286
10.2217/nnm-2020-0286 · External reference
Dexamethasone nanomedicines for COVID-19
10.1038/s41565-020-0752-z · 2020 · External reference
10.1016/j.jconrel.2015.08.007
10.1016/j.jconrel.2015.08.007 · External reference
